Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine-Reference-Cited by-同舟云学术

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine

Published:2011-12 Issue:12 Volume:30 Page:1086-1091
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Frenck Robert,Thompson Allison,Yeh Sylvia H.,London Arnold,Sidhu Mohinder S.,Patterson Scott,Gruber William C.,Emini Emilio A.,Scott Daniel A.,Gurtman Alejandra

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology, and Child Health

Reference31 articles.

1. . Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.;Whitney;N Engl J Med,2003

2. . Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.;Pilishvili;J Infect Dis,2010

3. . The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007.;Bettinger;Vaccine,2010

4. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniaeMassachusetts, 2001-2006.;MMWR,2007

5. . Serotype 19A is the most common serotype causing invasive pneumococcal infections in children.;Kaplan;Pediatrics,2010

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age;Pediatric Infectious Disease Journal;2024-03-15

2. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age;Human Vaccines & Immunotherapeutics;2023-08

3. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION);Vaccine;2023-01

4. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN);Vaccine;2022-10

5. The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol;Wellcome Open Research;2022-06-16